Vinorelbine Induces Apoptosis and Caspase-3 (CPP32) Expression in Leukemia and Lymphoma Cells: A Comparison with Vincristine

References

• Thompson C.B. Apoptosis in the pathogenesis and treatment of disease. Science 1995; 267: 1456–1462
   PubMed Web of Science ®Google Scholar
• Blogosklonny M.V., Giannakakou P., El Deiry W.S., et al. Raf-1/bcl-2 phosphorylation: a step from microtubule damage to ceil death. Cancer Res 1997; 7: 130–135
   Google Scholar
• Johnson S.A., Harper P., Hortobagyi G.N., et al. Vinorelbine: an overview. Cancer Treat Rev 1996; 22: 127–142
   PubMed Web of Science ®Google Scholar
• Armitage J.O. Treatment of non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1023–1030
   PubMed Web of Science ®Google Scholar
• Devizzi L., Santoro A., Bonfante V., et al. Vinorelbine: a new promising drug in Hodgkin's disease. Leukemia and Lymphoma 1996; 22: 409–414
   PubMed Web of Science ®Google Scholar
• Bruno S., Savignano R., Corrado C., et al. Vinorelbine (NVB): a new alkaloid active in refractory / relapsed lymphomas. A phase II study. Proc Am Soc Clin Oncol 1994; 13: 383
   Google Scholar
• Rowinsky E.K., Donehower R.C. Antimicrotubule agents. Cancer Chemotherapy and Biotherapy. Principles and Practice, Second Edition, B.A. Chabner, D.L. Longo. Lippincott-Raven Publishers. 1996; 263–296
   Google Scholar
• Koopman G., Reutelingsperger C.P.M., Kuitjten G.A.M., et al. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 1994; 84: 1415–1420
   PubMed Web of Science ®Google Scholar
• Hermann S. Mechanisms and genes of cellular suicide. Science 1995; 267: 1445–1449
   PubMed Web of Science ®Google Scholar
• Gottschalk A.R., Boise L.H., Oltvai Z.N., et al. The ability of Bcl-xL and Bcl-2 to prevent apoptosis can be differentially regulated. Cell Death and Differentiation 1996; 3: 113–118
   PubMed Web of Science ®Google Scholar
• Miyashita T., Reed J.C. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 1993; 81: 151–157
   PubMed Web of Science ®Google Scholar
• Tewari M., Quan L.T., O'Rourke K., et al. Yama / CPP32β, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly (ADP-Ribose) polymerase. Cell 1995; 81: 801–809
   PubMed Web of Science ®Google Scholar
• Alnemri E.S., Livingston D.J., Nicholson D.W., et al. Human ICE/CED-3 Protease Nomenclature (Letter to the Editor). Cell 1996; 87: 171
   PubMed Web of Science ®Google Scholar
• Wang X., Zelenski N.G., Yang J., et al. Cleavage of sterol regulatory element binding proteins (SREBPs) by CPP32 during apoptosis. The EMBO J 1996; 15: 1012–1020
   PubMed Web of Science ®Google Scholar
• Datta R., Banach D., Kojima H., et al. Activation of the CPP32 protease in apoptosis induced by 1-β-darabinofura-nosylcytosine and other DNA-damaging agents. Blood 1996; 88: 1936–1943
   PubMed Web of Science ®Google Scholar
• Erhadt P., Cooper G.M. Activation of the CPP32 apoptotic protease by distinct signalling pathways with differential sensitivity to Bcl-xL. J Biol Chem 1996; 271: 17601–17604
   PubMed Web of Science ®Google Scholar
• Kauffman S.H., Desnoyers S., Ottaviano Y., et al. Specific proteolytic cleavage of poly (ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res 1993; 53: 3976–3985
   PubMed Web of Science ®Google Scholar
• Liu X., Kim C.N., Pohl J., et al. Purification and characterization of an interleukin-l(5-converting enzyme family protease that activates cysteine protease P32 (CPP32). J Biol Chem 1996; 271: 13371–13376
   PubMed Web of Science ®Google Scholar
• Wang X., Sato R., Brown M.S., et al. SREBP-1, a membrane-bound transcription factor released by sterol-regulated proteolysis. Cell 1994; 77: 53–62
   PubMed Web of Science ®Google Scholar
• Huschtscha L.I., Jeitner T.M., Andersson C.E., et al. Identification of apoptotic and necrotic human leukemic cells by flow cytometry. Exp Cell Res 1994; 212: 161–165
   PubMed Web of Science ®Google Scholar
• Chang Y.F., Li L.L., Wu C.W., et al. Paclitaxel-induced apoptosis in human gastric cell lines. Cancer 1996; 77: 14–18
   PubMed Web of Science ®Google Scholar
• Kerr J.F.R., Winterford C.M., Harmon B.V. Apoptosis. Its significance in cancer and cancer therapy. Cancer 1994; 73: 2013–2026
   PubMed Web of Science ®Google Scholar
• Dive C., Hickman J.A. Drug-target interactions: only the first step in the commitment to a programmed cell death?. Br J Cancer 1991; 64: 192–196
   PubMed Web of Science ®Google Scholar
• Aisenberg A.C. Coherent view of non-Hodgkin's lymphoma. J Clin Oncol 1995; 13: 2656–2675
   PubMed Web of Science ®Google Scholar
• Fisher R.I., Gaynor E.R., Dahlberg S., et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced Non-Hodgkin's lymphoma. N Eng J Med 1993; 328: 1002–1006
   PubMed Web of Science ®Google Scholar
• Dive C., Gregory C.D., Phipps D.J., et al. Analysis and discrimination of necrosis and apoptosis (programmed cell death) by multiparameter flow cytometry. Biochica et Biophysica Acta 1992; 1133: 275–285
   PubMed Web of Science ®Google Scholar
• Arends M.J., Morris R.G., Wyllie A.H. Apoptosis: the role of the endonuclease. Am J Pathol 1990; 136: 593–608
   PubMed Web of Science ®Google Scholar
• Huschtscha L.I., Bartier W.A., Andersson Ross C.E., et al. Characteristics of cancer cell death after exposure to cytotoxic drugs in vitro. Br J Cancer 1996; 73: 54–60
   PubMed Web of Science ®Google Scholar
• Kingma D.W., Weiss W.B., Jaffe E.S., et al. Epstein-Barr Virus latent membrane protein-1 oncogene deletions: correlations with malignancy in Epstein-Barr Virus-associated lymphoproliferative disorders and malignant lymphomas. Blood 1996; 88: 242–251
   PubMed Web of Science ®Google Scholar
• Murray P.G., Swinnen L.J., Constandinou C.M., et al. Bcl-2 but not its Epstein-Barr virus-encoded homo-logue, BHRF-1, is commonly expressed in posttransplantation lymphoproliferative disorders. Blood 1996; 87: 706–711
   PubMed Web of Science ®Google Scholar
• Parchment R.E. The implications of a unified theory of programmed cell death, polyamines, oxyradicals and histogenesis in the embryo. Int J Dev Biol 1993; 37: 75–83
   PubMed Web of Science ®Google Scholar
• Wahl A.F., Donaldson K.L., Fairchild C., et al. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nature Med 1996; 2: 72–79
   PubMed Web of Science ®Google Scholar
• Martin S.J., Reutelsperger C.P.M., Mc Gahon A.J., et al. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus. Inhibition by overexpression of Bcl-2 and Abl. J Exp Med 1995; 182: 1545–1556
   PubMed Web of Science ®Google Scholar
• Kane A.B. Redefining cell death (Commentary). Am J Pathol 1995; 146: 1–2
   PubMed Web of Science ®Google Scholar
• Tsujimoto Y., Shimizu S., Eguchi Y., et al. Bcl-2 and Bcl-xL block apoptosis as well as necrosis: possible involvement of common mediators in apoptotic and necrotic signal transduction pathways. Leukemia 1997; 11(suppl 3)380–382
   PubMedGoogle Scholar
• Martin S.J., Finucane D.M., Amarante-Mendes G.P., et al. Phosphatidylserine externalization during CD-95-induced apoptosis of both cells and cytoplasts requires ICE/CED-3 protease activity. J Biol Chem 1996; 271: 28753–28756
   PubMed Web of Science ®Google Scholar
• Barinaga M. Forging a path to cell death. Science 1996; 273: 735–737
   PubMed Web of Science ®Google Scholar
• Ibrado A.M., Huang Y., Fang G., et al. Over-expression of Bcl-2 or Bcl-xL inhibits Ara-C-induced CPP32/ Yama protease activity and apoptosis of human acute myeloid leukemia HL-60 cells. Cancer Res 1996; 56: 4743–4748
   PubMed Web of Science ®Google Scholar
• Ferme C., Bastiow Y., Lepage E., et al. The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease. Am Oncol. 1995; 6: 543–549
   Google Scholar